Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1668525 | 0.89 | GPR119 (0.52) | GPR119RORCMAPK1L3MBTL1LMNA | |
| SCHEMBL1669016 | 0.88 | GPR119 (0.56) | GPR119MAPK1L3MBTL1LMNAKMT2A | |
| SCHEMBL1668547 | 0.87 | GPR119 (0.49) | GPR119RORCMAPK1L3MBTL1LMNA | |
| SCHEMBL1668836 | 0.86 | GPR119 (0.56) | GPR119PDE4BMAPK1L3MBTL1LMNA | |
| SCHEMBL2514804 | 0.84 | GPR119 (0.52) | GPR119RORCLMNAKMT2AFPR2 | |
| SCHEMBL1671302 | 0.84 | GPR119 (0.62) | GPR119RORCLMNAKMT2AFPR2 | |
| SCHEMBL1668356 | 0.83 | GPR119 (0.46) | GPR119RORCMAPK1L3MBTL1LMNA | |
| SCHEMBL1668527 | 0.83 | GPR119 (0.46) | GPR119RORCMAPK1L3MBTL1LMNA | |
| SCHEMBL1668891 | 0.82 | GPR119 (0.48) | GPR119RORCLMNAKMT2AHTT | |
| SCHEMBL1668403 | 0.77 | GPR119 (0.44) | GPR119PDE4BRORCMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | claimed |
| EP-2486033-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2012-08-15 | — | — | EP | claimed |
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-06 | — | — | US | claimed |
| WO-2011044001-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-04-14 | — | — | WO | claimed |
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | disclosed |
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | disclosed |
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | disclosed |
| EP-2486033-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2012-08-15 | — | — | EP | disclosed |
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-06 | — | — | US | disclosed |
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-06 | — | — | US | disclosed |
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-06 | — | — | US | disclosed |
| WO-2011044001-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044001-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GPR119 1/4885PDE4B 402/4885RORC 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.